UnitedHealth AI Stock Analysis
Want to see UNH full AI Analyst Report?
UnitedHealth (UNH) AI Stock Analysis
UnitedHealth
(NYSE:UNH)
UNH scores highest on financial quality and earnings-call fundamentals (strong absolute cash generation and reaffirmed long-term growth outlook with updated EPS guidance), but the overall score is held back by weakening recent trajectory (TTM revenue decline and margin compression) and clearly weak technicals with the stock trading below major moving averages. Valuation is supportive but not compelling enough to offset the bearish price trend and cost/margin risks highlighted on the call.
UnitedHealth Key Performance Indicators (KPIs)
Revenue by TypeCategorizes income by source, such as premiums, services, or products, revealing diversification and potential vulnerabilities in revenue streams.
Products remain the primary growth engine, but recent momentum has broadened as Services continues a steady recovery rather than merely tracking enrollment. That mix is strategically encouraging: Medicare Advantage margin recovery, stronger Optum Health execution, and external Optum Rx membership can support more durable recurring revenue. Investment and Other remains volatile and should not be treated as a dependable contributor, leaving UnitedHealth’s outlook more dependent on operating businesses and their ability to offset elevated medical costs and commercial utilization pressure.
UnitedHealth (UNH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $296.12B
- Dividend Yield
- 2.74%
- Average Volume (3M)
- 5.72M
- Price to Earnings (P/E)
- 18.9
- Beta (1Y)
- 0.36
- Revenue Growth
- 3.33%
- EPS Growth
- -8.75%
- Country
- US
- Employees
- 390,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
UnitedHealth Business Overview & Revenue Model
Company Description
UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthc...
How the Company Makes Money
UnitedHealth primarily makes money through (1) health insurance and benefit administration and (2) health services, with revenue and earnings generated across its two main segments. 1) UnitedHealthcare (health benefits) - Premium revenue: A major sou...
UnitedHealth Earnings Call Summary
The call was predominantly positive, with improved third-quarter earnings, a lower medical care ratio, raised 2026 adjusted EPS guidance, Medicare Advantage margin recovery, strong Optum operating metrics, AI and modernization progress, capital returns, and confidence in 2027 growth. The main challenges were persistently high medical costs, commercial trends above 11%, negative Medicaid core margins, No Surprises Act arbitration costs, and continued policy and funding pressures.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
UnitedHealth Group reaffirmed its 13%-16% long-term target growth range, views the lower end of its long-term 13%-16% growth rate as a more reasonable starting point for 2027, and updated 2026 adjusted EPS guidance to at least $20.50; it expects debt-to-cap ratio to approach 40% by year-end, dividends to exceed $8 billion by year-end, 2026 core Medicaid margins to be moderately better than negative 1%, and 2026 Medicare margins to be near the top end of the 2%-4% range. For 2027, more than 94% of Medicare-eligible individuals nationwide will have access to a UnitedHealthcare Medicare plan, approximately 90% will have access to a Medicare Advantage plan with a $0 premium option, chronic special needs plans will be available to nearly 50 million Medicare-eligible individuals, and the company expects to approach 75% of total members in four-plus Star plans compared to the industry average of 70%; Optum Health remains paced toward its 6%-8% target margin range by 2028, while Optum Insight expects meaningful progress in 2027, setting the foundation for accelerating growth in 2028 and beyond.
UnitedHealth Financial Statement Overview
Summary
Strong overall fundamentals supported by robust operating cash flow ($26.2B TTM) and free cash flow ($22.8B TTM) plus a large equity base (~$104B TTM) and solid ROE (~22% TTM). Offsetting this strength are a TTM revenue decline (-10.4%) and notable margin compression (net margin ~3.5% TTM vs ~6% in 2022–2023), alongside meaningful leverage (~$74B debt).
Income Statement
74PositiveBalance Sheet
72PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 449.66B | 447.57B | 400.28B | 371.62B | 324.16B | 287.60B |
| Gross Profit | 102.58B | 82.92B | 89.40B | 90.96B | 79.62B | 69.65B |
| EBITDA | 27.99B | 23.06B | 28.08B | 36.33B | 31.84B | 27.07B |
| Net Income | 15.88B | 12.06B | 14.40B | 22.38B | 20.12B | 17.29B |
Balance Sheet | ||||||
| Total Assets | 312.78B | 309.58B | 298.28B | 273.72B | 245.71B | 212.21B |
| Cash, Cash Equivalents and Short-Term Investments | 28.55B | 28.12B | 29.11B | 29.63B | 27.91B | 23.91B |
| Total Debt | 74.33B | 78.39B | 76.90B | 67.44B | 57.62B | 46.00B |
| Total Liabilities | 207.24B | 207.88B | 195.69B | 174.80B | 159.36B | 135.73B |
| Stockholders Equity | 98.10B | 94.11B | 92.66B | 88.76B | 77.77B | 71.76B |
Cash Flow | ||||||
| Free Cash Flow | 22.83B | 16.07B | 20.70B | 25.68B | 23.40B | 19.89B |
| Operating Cash Flow | 26.20B | 19.70B | 24.20B | 29.07B | 26.21B | 22.34B |
| Investing Cash Flow | -11.43B | -8.69B | -20.53B | -15.57B | -28.48B | -10.37B |
| Financing Cash Flow | -16.06B | -11.64B | -3.51B | -11.53B | 4.23B | -7.46B |
UnitedHealth Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNH, the sentiment is Negative. The current price of 330.48 is below the 20-day moving average (MA) of 398.43, below the 50-day MA of 389.44, and below the 200-day MA of 365.47, indicating a bearish trend. The MACD of -7.49 indicates Positive momentum. The RSI at 24.23 is Positive, neither overbought nor oversold. The STOCH value of 8.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNH.
UnitedHealth Risk Analysis
UnitedHealth disclosed 21 risk factors in its most recent earnings report. UnitedHealth reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
2 New RisksUnitedHealth Peers Comparison
Overall Rating
ELV76Outperform
CI75Outperform
CVS71Outperform
UNH67Neutral
CNC66Neutral
HUM55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $84.30B | 16.62 | 11.59% | 1.76% | 3.60% | -4.06% | |
| 75Outperform | $71.95B | 12.02 | 14.10% | 2.27% | 6.79% | -0.38% | |
| 71Outperform | $102.41B | 9.24 | 14.13% | 3.32% | 6.77% | 2114.64% | |
| 67Neutral | $296.12B | 18.86 | 16.35% | 2.74% | 3.33% | -8.75% | |
| 66Neutral | $32.47B | 22.16 | 6.78% | ― | 9.71% | ― | |
| 55Neutral | $45.64B | 36.61 | 6.70% | 0.93% | 22.02% | -3.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UNH | Unitedhealth Group Inc. | 330.48 | 18.81 | 6.03% | |
| CNC | Centene | 65.58 | 29.08 | 79.67% | |
| CI | Cigna | 273.04 | 1.11 | 0.41% | |
| CVS | CVS Health Corp | 80.04 | 4.34 | 5.73% | |
| HUM | Humana | 380.00 | 155.83 | 69.51% | |
| ELV | Elevance Health, Inc. | 390.16 | 74.70 | 23.68% |
UnitedHealth Corporate Events
UnitedHealth Appoints Madeline Bell as Independent Director
NeutralUnitedHealth Group announced on Nov. 9, 2026, the appointment of Madeline S. Bell as an independent director, effective Nov. 3, 2026. Bell was the former president and CEO of Children’s Hospital of Philadelphia, where she held a four-decade career an...
UnitedHealth to Present Strategy at Wells Fargo Conference
NeutralUnitedHealth Group senior leaders will participate in an interview-style discussion at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:00 a.m. Eastern Time, addressing the company’s strategy, market positions,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
